ICI settles US dispute
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.IMPERIAL Chemical Industries is to pay dollars 21m ( pounds 14.6m) to Barr Laboratories, the US generic drugs manufacturer, as part of a settlement of a legal dispute over the US patent for Nolvadex, ICI's best-selling breast-cancer drug.
Under the agreement, Barr will be able to sell a generic version of Nolvadex in November, although ICI will supply it with the product. The terms of the distribution agreement were not disclosed, but ICI said it was 'commercially satisfactory' to both companies.
Barr alleged that ICI had failed to submit all relevant technical data on Nolvadex when it filed its patent application in the US, a claim that was upheld by the southern district court of New York last April. Although ICI appealed, it also started discussions with Barr. The settlement is contingent on the judgment being set aside - leaving the patent valid - and the case dismissed.
ICI said yesterday that both parties agreed 'there was a substantial possibility' that the patent would have been held valid and enforceable, while Barr admitted that the appeal raised genuine issues. But a spokesman for ICI said the settlement removed uncertainty.
'We felt it was better to have the certainty of an out-of-court settlement than the expense and inconvenience of litigation,' he said. Analysts say the group may also have been keen to resolve the dispute before the demerger of Zeneca, ICI's pharmaceuticals arm, in the summer.
Although Nolvadex is a relatively old drug, it has been given a new lease of life as a treatment for breast cancer. Its US sales in 1992 were dollars 265m, and its patent is not due to expire until 2002.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments